CRISPR Unlocks a New Way to Defeat Resistant Lung Cancer

CRISPR unlocks a new way to defeat resistant lung cancer

Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor growth. The technique worked even when only a fraction of tumor cells were edited, making it practical for real-world treatment. Since NRF2 fuels resistance in several cancers, the approach could have broad impact.

CRISPR breakthrough reverses chemotherapy resistance in lung cancer

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in lung cancer. The approach restores drug sensitivity and slows tumor growth. The findings are published in the journal Molecular Therapy Oncology.

New study reverses chemotherapy resistance in lung cancer

A major breakthrough in cancer research has shown that using CRISPR gene editing technology to turn off a specific gene can help fight chemotherapy resistance in lung cancer. This discovery could open the door to new treatments that make current cancer drugs work better. The study was led by scientists at ChristianaCare’s Gene Editing Institute […] The post New study reverses chemotherapy resistance in lung cancer appeared first on Knowridge Sci…

CRISPR Gene Editing Reverses Chemotherapy Resistance in Lung Cancer

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in lung cancer. The approach restores drug sensitivity and slows tumor growth.

CRISPR breakthrough reverses chemotherapy resistance in lung cancer. In a major step forward for cancer care, researchers have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in lung cancer. The approach resto